In today’s briefing:
- #80 India Insight: Bajaj Finance Adds 5M Users, Electronics Production Aim $500B, HDFC Gains RBI Nod
- APAC Healthcare Weekly (Jan 5)- Beigene, Innovent Biologics, CSPC Pharma, Hutchmed, Yuhan, Lupin
#80 India Insight: Bajaj Finance Adds 5M Users, Electronics Production Aim $500B, HDFC Gains RBI Nod
- Bajaj Finance Ltd (BAF IN) reported strong Q3 FY25 growth, with a 28% rise in AUM, 22% increase in loans issued, and a 19% rise in deposits.
- India aims to reach $500 billion in electronics production by 2030, focusing on mobile phones, IT hardware, and wearables. The PLI scheme will support supply chain growth.
- HDFC Bank (HDFCB IN) has received RBI approval to acquire up to 9.5% stakes in Kotak Mahindra, AU Small Finance, and Capital Small Finance Banks through its subsidiaries
APAC Healthcare Weekly (Jan 5)- Beigene, Innovent Biologics, CSPC Pharma, Hutchmed, Yuhan, Lupin
- BeiGene has received FDA approved for Tevimbra for the first-line treatment of certain types of gastric cancers. Innovent announced a collaboration and exclusive license agreement with Roche for an ADC.
- CSPC Pharmaceutical got clinical trial approval in China for Leuprorelin extended-release Injection. Sichuan Kelun-Biotech received China approval for tagitanlimab in nasopharyngeal cancer.
- Hutchmed China is divesting its 45% equity interest in joint venture for $608M. Yuhan Corp has received European approval for its lung cancer drug Leclaza.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
